Gutschmidt, Kristina
Musumeci, Olimpia
Díaz-Manera, Jordi
Chien, Yin-Hsiu
Knop, Karl Christian
Wenninger, Stephan
Montagnese, Federica
Pugliese, Alessia
Tavilla, Graziana
Alonso-Pérez, Jorge
Hwu, Paul Wuh-Liang
Toscano, Antonio
Schoser, Benedikt https://orcid.org/0000-0002-2757-8131
Funding for this research was provided by:
Sanofi Genzyme
Projekt DEAL
Article History
Received: 10 September 2020
Revised: 11 December 2020
Accepted: 13 January 2021
First Online: 5 February 2021
Compliance with ethical standards
:
: KG, FM, SW received travel support and speaker honoraria from Sanofi Genzyme. BS received funding for research, honoraria for the participation of advisory board meetings and consulting, and speaker fees from Sanofi Genzyme, Amicus therapeutic, Audentes therapeutics, Nexien, and Lupin. AT and JDM received honoraria for the participation of advisory board meetings and for teaching activities, KCK received lecture fees and advisory boards from Sanofi-Genzyme and Lupin. All other authors declare that they have no conflicts of interest.
: The study was approved by the Ethics Committee of the Ludwig Maximilian University of Munich, Germany (IRB vote 231-16) in 2016 and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All patients gave an informed consent for their participation in the study and publication of the results.